MedTrace Logo

Outcome Analysis of Aspirin in Liver Transplantation

NCT04327427 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2020-03-31

No results posted yet for this study

Summary

In the experimental setting inhibition of platelet activation was able to reduce immune-mediated necroinflammatory liver disease and consecutively hepatocellular carcinoma development. Therefore, antiplatelet therapy may not only have a preventive effect on hepatic artery patency but also on tumor recurrence.

So far and to the best of our knowledge, no study investigated the effect of antiplatelet therapy on hepatic arterial patency, tumor recurrence and graft survival after primary liver transplantation.

Conditions

  • Liver Transplant; Complications

Interventions

OTHER

Aspirin

Outcome Analysis of Aspirin in liver transplantation

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Christian E Oberkofler, MD · University of Zurich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-10-01
Completion
2021-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04327427 on ClinicalTrials.gov